EQS-News: PharmaSGP convenes extraordinary general meeting to resolve on Squeeze-out

PharmaSGP convenes extraordinary general meeting to resolve on Squeeze-out

Gräfelfing, September 22, 2025 – As already announced in the ad hoc announcement by PharmaSGP Holding SE on July 24, 2025, FUTRUE GmbH informed PharmaSGP Holding SE on July 24, 2025 that it owns more than 95% of the shares in PharmaSGP Holding SE within the meaning of Section 327a of the German Stock Corporation Act (AktG) and that, pursuant to Section 327a para. 1 AktG, the general meeting of PharmaSGP Holding SE should resolve to transfer the shares of the remaining shareholders of PharmaSGP Holding SE to FUTRUE GmbH in return for an appropriate cash compensation (so-called squeeze-out).

Meanwhile, FUTRUE GmbH specified its request after the necessary valuation had been conducted, stating the cash compensation it has determined. This cash compensation amounts to EUR 29.33 for each no-par value bearer share in PharmaSGP Holding SE.

Based on this specified request, PharmaSGP Holding SE has today convened an extraordinary general meeting for October 31, 2025, which is to resolve on the transfer of the shares of the remaining shareholders to FUTRUE GmbH in return for the aforementioned appropriate cash compensation. Further information and documents relating to the extraordinary general meeting are available on the company's website.

The squeeze-out will take effect subject to the approval of the general meeting and the registration of the transfer resolution with the commercial register of PharmaSGP Holding SE.

CONTACT

cometis AG
Jakob Hafer
Phone: +49-611-20585522
Email: ir@pharmasgp.com

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company’s core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX^® for rheumatic pain and Restaxil^® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan^®, Formigran^®, Spalt^® and Kamol^®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2024, PharmaSGP generated revenues of EUR 118.8 million at an adjusted EBITDA margin of 31.3%.